Targeting B Lymphocytes as Therapy for ANCA-Associated Vasculitis

Jason M. Golbin, Ulrich Specks

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

This article focuses on the initial results achieved with the more selective immunosuppressive approach of B-lymphocyte depletion in patients who fail cyclophosphamide or have contraindications for its use in the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). This novel approach has sparked hope for patients and physicians in their search for effective, well-tolerated therapy for AAV. B-cell depletion is now undergoing rigorous investigation in randomized clinical trials.

Original languageEnglish (US)
Pages (from-to)741-754
Number of pages14
JournalRheumatic Disease Clinics of North America
Volume33
Issue number4
DOIs
StatePublished - Nov 2007

Fingerprint

Antineutrophil Cytoplasmic Antibodies
Vasculitis
B-Lymphocytes
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Lymphocyte Depletion
Immunosuppressive Agents
Cyclophosphamide
Randomized Controlled Trials
Physicians
Therapeutics

ASJC Scopus subject areas

  • Rheumatology

Cite this

Targeting B Lymphocytes as Therapy for ANCA-Associated Vasculitis. / Golbin, Jason M.; Specks, Ulrich.

In: Rheumatic Disease Clinics of North America, Vol. 33, No. 4, 11.2007, p. 741-754.

Research output: Contribution to journalArticle

@article{04b6387a9da84be185d76739c9da2026,
title = "Targeting B Lymphocytes as Therapy for ANCA-Associated Vasculitis",
abstract = "This article focuses on the initial results achieved with the more selective immunosuppressive approach of B-lymphocyte depletion in patients who fail cyclophosphamide or have contraindications for its use in the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). This novel approach has sparked hope for patients and physicians in their search for effective, well-tolerated therapy for AAV. B-cell depletion is now undergoing rigorous investigation in randomized clinical trials.",
author = "Golbin, {Jason M.} and Ulrich Specks",
year = "2007",
month = "11",
doi = "10.1016/j.rdc.2007.09.001",
language = "English (US)",
volume = "33",
pages = "741--754",
journal = "Rheumatic Disease Clinics of North America",
issn = "0889-857X",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Targeting B Lymphocytes as Therapy for ANCA-Associated Vasculitis

AU - Golbin, Jason M.

AU - Specks, Ulrich

PY - 2007/11

Y1 - 2007/11

N2 - This article focuses on the initial results achieved with the more selective immunosuppressive approach of B-lymphocyte depletion in patients who fail cyclophosphamide or have contraindications for its use in the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). This novel approach has sparked hope for patients and physicians in their search for effective, well-tolerated therapy for AAV. B-cell depletion is now undergoing rigorous investigation in randomized clinical trials.

AB - This article focuses on the initial results achieved with the more selective immunosuppressive approach of B-lymphocyte depletion in patients who fail cyclophosphamide or have contraindications for its use in the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). This novel approach has sparked hope for patients and physicians in their search for effective, well-tolerated therapy for AAV. B-cell depletion is now undergoing rigorous investigation in randomized clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=36248952098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36248952098&partnerID=8YFLogxK

U2 - 10.1016/j.rdc.2007.09.001

DO - 10.1016/j.rdc.2007.09.001

M3 - Article

VL - 33

SP - 741

EP - 754

JO - Rheumatic Disease Clinics of North America

JF - Rheumatic Disease Clinics of North America

SN - 0889-857X

IS - 4

ER -